Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.31
+0.01 (0.14%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Arvinas Revenue
Arvinas had revenue of $249.70M in the quarter ending June 30, 2026, with 1,014.73% growth. This brings the company's total for the last twelve months to $316.70M, down -15.05% year-over-year. In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%. That makes Arvinas the 14,150th largest company in the world by revenue and 2,578th in the United States.
Revenue (ttm)
$316.70M
Revenue Growth
-15.05%
P/S Ratio
1.51
Revenue / Employee
$1,287,398
Employees
246
Market Cap
477.97M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| CytomX Therapeutics | 18.30M |
| Surrozen | 11.51M |
| Oculis Holding AG | 1.45M |
| Neurogene | 925.00K |
| Entera Bio | 42.00K |
ARVN News
- 19 days ago - Arvinas presents data from clinical trial of ARV-102 - TheFly
- 19 days ago - Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease - GlobeNewsWire
- 25 days ago - Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 27 days ago - Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Arvinas announces first patient dosed in Phase 1/2 trial of ARV-6723 - TheFly
- 4 weeks ago - Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate - GlobeNewsWire
- 5 weeks ago - Arvinas Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Arvinas Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts